T. Rowe Price Associates
MBX

T. Rowe Price Associates’s MBX Biosciences MBX Stock Holding History

T. Rowe Price Associates’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45M Sell
814,807
-214,200
-21% -$7.48M ﹤0.01% 920
2026
Q1 		$30.7M Buy
1,029,007
+188,501
+22% +$6.41M ﹤0.01% 924
2025
Q4 		$26.5M Sell
840,506
-114,220
-12% -$2.77M ﹤0.01% 995
2025
Q3 		$16.7M Sell
954,726
-392,184
-29% -$5.24M ﹤0.01% 1095
2025
Q2 		$15.4M Buy
1,346,910
+245,994
+22% +$2.51M ﹤0.01% 1016
2025
Q1 		$8.13M Sell
1,100,916
-60,611
-5% -$641K ﹤0.01% 1149
2024
Q4 		$21.4M Sell
1,161,527
-31,411
-3% -$669K ﹤0.01% 982
2024
Q3 		$31M Buy
+1,192,938
New +$27.3M ﹤0.01% 882

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

T. Rowe Price Associates's MBX Position: Q2 2026 in Review

T. Rowe Price Associates reduced its MBX Biosciences (MBX) stake by 21% in Q2 2026, selling an estimated $7.48M and leaving 814,807 shares worth $45M. The position accounts for ﹤0.01% of the portfolio, ranked #920.

T. Rowe Price Associates first reported a position in MBX in Q3 2024 and has held it in 8 quarters since. 172 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • T. Rowe Price Associates held 814,807 shares of MBX Biosciences worth $45M as of Q2 2026.
  • T. Rowe Price Associates sold 214,200 MBX Biosciences shares in Q2 2026, an estimated $7.48M.
  • MBX Biosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #920 holding.
  • T. Rowe Price Associates first reported a position in MBX Biosciences in Q3 2024 and has held it in 8 quarters since.
  • 172 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.